m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00579)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
Mdm2
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: 2.07E+00 p-value: 7.73E-92 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting E3 ubiquitin-protein ligase Mdm2 (Mdm2)/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/p21), and downregulation of mdm2. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | ||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell cycle | hsa04110 | |||
Cell Process | Cell apoptosis | |||
Cells in G2/M phase decreased | ||||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
MOLT-4 | Adult T acute lymphoblastic leukemia | Homo sapiens | CVCL_0013 | |
Kasumi-1 | Myeloid leukemia with maturation | Homo sapiens | CVCL_0589 | |
K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 | |
HL-60 | Adult acute myeloid leukemia | Homo sapiens | CVCL_0002 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
CCRF-CEM C7 | T acute lymphoblastic leukemia | Homo sapiens | CVCL_6825 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
Methyltransferase-like 14 (METTL14) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting E3 ubiquitin-protein ligase Mdm2 (Mdm2)/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/p21), and downregulation of mdm2. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | ||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell cycle | hsa04110 | |||
Cell Process | Cell apoptosis | |||
Cells in G5/M phase decreased | ||||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
MOLT-4 | Adult T acute lymphoblastic leukemia | Homo sapiens | CVCL_0013 | |
Kasumi-1 | Myeloid leukemia with maturation | Homo sapiens | CVCL_0589 | |
K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 | |
HL-60 | Adult acute myeloid leukemia | Homo sapiens | CVCL_0002 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
CCRF-CEM C7 | T acute lymphoblastic leukemia | Homo sapiens | CVCL_6825 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
Acute myeloid leukaemia [ICD-11: 2A60]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting E3 ubiquitin-protein ligase Mdm2 (Mdm2)/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/p21), and downregulation of mdm2. | |||
Responsed Disease | Acute myeloid leukaemia [ICD-11: 2A60] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell cycle | hsa04110 | |||
Cell Process | Cell apoptosis | |||
Cells in G5/M phase decreased | ||||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
MOLT-4 | Adult T acute lymphoblastic leukemia | Homo sapiens | CVCL_0013 | |
Kasumi-1 | Myeloid leukemia with maturation | Homo sapiens | CVCL_0589 | |
K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 | |
HL-60 | Adult acute myeloid leukemia | Homo sapiens | CVCL_0002 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
CCRF-CEM C7 | T acute lymphoblastic leukemia | Homo sapiens | CVCL_6825 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting E3 ubiquitin-protein ligase Mdm2 (Mdm2)/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/p21), and downregulation of mdm2. | |||
Responsed Disease | Acute myeloid leukaemia [ICD-11: 2A60] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell cycle | hsa04110 | |||
Cell Process | Cell apoptosis | |||
Cells in G2/M phase decreased | ||||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
NB4 | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | |
MV4-11 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0064 | |
MOLT-4 | Adult T acute lymphoblastic leukemia | Homo sapiens | CVCL_0013 | |
Kasumi-1 | Myeloid leukemia with maturation | Homo sapiens | CVCL_0589 | |
K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 | |
HL-60 | Adult acute myeloid leukemia | Homo sapiens | CVCL_0002 | |
HEL | Erythroleukemia | Homo sapiens | CVCL_0001 | |
CCRF-CEM C7 | T acute lymphoblastic leukemia | Homo sapiens | CVCL_6825 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |